Press Release on the standalone & consolidated Audited financial results for the Quarter and Year ended 31.03.2026

Mgmt Guided Margin ImprovementOrder Pipeline DisclosedInvestor Communications View source PDF

SAIPARENT · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve 14 horizons · vs prior close

-1.4%1-day move

₹490.00

prior close

₹508.00

base price

After-mkt

timing

5m10m15m30m1D2D3D4D5D7D15D1M2M3M

-1.8-3.8-2.7-2.4-1.4-0.7-1.2+4.1+2.0+11.3+16.9+20.0+13.9—

Up moveDown movePending

AI summary

Sai Parenterals reported exceptional Q4 FY26 results with revenue of ₹197.93 Cr, up 166.65% YoY, driven by full consolidation of its Australian subsidiaries acquired in November 2025. EBITDA surged 366.79% to ₹28.97 Cr and PAT jumped 736% to ₹13.25 Cr. For full year FY26, consolidated revenue reached ₹380.99 Cr (up 140.37%) with PAT at ₹14.37 Cr (up 45.52%). The company successfully completed its IPO in March 2026, raising ₹285 crore, and CDMO exports revenue surged over 250% YoY. Management has guided for FY27 revenue target of ₹750 crore with EBITDA margins improving to 17%.

Likely market impact

Strong quarter and full-year performance demonstrates operating leverage from scale and new subsidiaries. The FY27 margin guidance of 17% (vs 12.39% in FY26) signals continued profitability improvement as capex projects complete and new dossiers are commercialized.